
|Articles|June 1, 2004
Eyetech deal gives quick access to new research
New York-Eyetech Pharmaceuticals and Archemix Corp. will collaborate on the research and development of aptamers for use in the treatment of ophthalmic diseases.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Starting from scratch on neovascular age-related macular degeneration
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
AAO 2025: Early optogenetic therapy shows promise for patients with inherited retinal diseases
4
Subretinal drusenoid deposits in Black and Hispanic patients with AMD
5


















































.png)


